Neovasc Inc. P/FCF ratio

P/FCF ratio of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/FCF ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its free cash flow per share. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low P/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current P/FCF ratio of Neovasc Inc. is 0.0 (as of December 31, 2021)
  • P/FCF ratio for the quarter ending March 31, 2022 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly P/FCF ratio decreased by NaN%
  • Annual P/FCF ratio for 2021 was 0.0 (a NaN% decrease from previous year)
  • Annual P/FCF ratio for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual P/FCF ratio for 2019 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/FCF ratio of Neovasc Inc.

Most recent P/FCF ratioof NVCN including historical data for past 10 years.

Interactive Chart of P/FCF ratio of Neovasc Inc.

Neovasc Inc. P/FCF ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0
2021 0.0 0.0 0.0 0.0 0.0
2020 0.0 0.0 0.0 0.0 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 2.91 2.82 3.72 0.0
2016 4.3 0.0 0.0 0.0 4.3
2015 0.0 0.0 0.0 0.0 0.0
2014 0.0 0.0 0.0 0.0 0.0
2013 0.0 0.0 0.0 0.0 0.0
2012 0.0 0.0 0.0 0.0 0.0
2011 0.0 0.0

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.